研究单位：[1]Beijing Kawin Technology Share-Holding Co., Ltd.[2]Tongji Hospital, Tongji Medical College Huazhong University of Science ＆ Technology Wuhan, Hubei, China[3]Union hospital, Tongji Medical College Huazhong University of Science ＆ Technology Wuhan, Hubei, China[4]Zhongnan Hospital of Wuhan University Wuhan, Hubei, China[5]The Second Xiangya Hospital of Central South University Changsha, Hunan, China[6]Xiangya Hospital Central-South University Changsha, Hunan, China[7]Jiangsu province hospital Nanjing, Jiangsu, China[8]The Second Hospital of Nanjing Nanjing, Jiangsu, China[9]First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China[10]The First Affiliated Hospital of Jilin University Changchun, Jilin, China[11]Yanbian University Hospital (Yanbian Hospital) Yanji, Jilin, China[12]The Sixth People's Hospital of Shenyang Shenyang, Liaoning, China[13]First Affiliated Hospital Of Medical College of Xian Jiaotong University Xi'an, Shaanxi, China[14]Second Affiliated Hospital Of Medical College of Xian Jiaotong University Xi'an, Shaanxi, China[15]Tangdu Hospital，Fourth Military Medical University Xi'an, Shaanxi, China[16]Jinan Infectious Disease Hospital Jinan, Shandong, China[17]Qilu Hospital of Shandong university Jinan, Shandong, China[18]The First Hospital of Shanxi Medical University Taiyuan, Shanxi, China[19]Sichuan Academy of Medical Science ＆Sichuan Provincial People's Hospital Chengdu, Sichuan, China[20]West China Hospital, Sichuan University Chengdu, Sichuan, China[21]The First Teaching Hospital of Xinjiang Medical University Urumqi, Xinjiang, China[22]The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang, China[23]Beijing Ditan Hospital, Capital Medical University Beijing, China
This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the treatment of Chronic hepatitis C who have not been previously treated with Interferon.
